DB Fitzpatrick & Co Inc Decreases Stake in Edwards Lifesciences Co. (NYSE:EW)

DB Fitzpatrick & Co Inc cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,534 shares of the medical research company’s stock after selling 472 shares during the quarter. Edwards Lifesciences makes up approximately 1.4% of DB Fitzpatrick & Co Inc’s portfolio, making the stock its 18th largest holding. DB Fitzpatrick & Co Inc’s holdings in Edwards Lifesciences were worth $1,520,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $32,000. Avior Wealth Management LLC lifted its position in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after acquiring an additional 308 shares in the last quarter. Peoples Bank KS bought a new position in shares of Edwards Lifesciences in the third quarter worth $40,000. Finally, Roble Belko & Company Inc purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $46,000. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,000 shares of company stock valued at $2,195,180. Corporate insiders own 1.27% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on EW. Barclays raised their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Finally, Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Trading Down 0.1 %

NYSE EW opened at $69.77 on Friday. The stock has a market cap of $41.15 billion, a P/E ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a 50 day simple moving average of $71.99 and a two-hundred day simple moving average of $71.60. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm’s revenue was up 8.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.59 earnings per share. On average, analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.